Every state, kept current
The Rates plan
$29/mo7-day free trialThis page shows one representative rate per state for Q5145. Full schedules include every locality, modifier, and age-band variant.
- Every code on all 51 published schedules
- Full-schedule CSV export and state network lists
- Email alerts when a state changes its rates
$29/mo after the trial. Cancel anytime.
Publishing states
16
Median % of Medicare
--
Rate range
$12.98 - $128.07
Q5145 rates in every publishing state
| State | Medicaid rate | % of Medicare | Prior auth | Vintage |
|---|---|---|---|---|
| Alabama | $12.98 | -- | -- | 2026 |
| Arkansas | $128.07* | -- | -- | 2026 |
| Arizona | $15.58 | -- | -- | 2025 |
| Indiana | $13.62 | -- | Required | 2025 |
| Kansas | $12.98 | -- | -- | 2025 |
| Kentucky | $128.07 | -- | -- | 2026 |
| Minnesota | $83.85 | -- | Required | 2025 |
| Mississippi | $21.30 | -- | -- | 2025 |
| Montana | $19.47 | -- | -- | 2026 |
| New Hampshire | $12.98 | -- | Not required | 2026 |
| New Jersey | $62.82 | -- | Not required | 2026 |
| New Mexico | $128.07 | -- | -- | 2025 |
| Oklahoma | $25.95 | -- | -- | 2026 |
| Texas | $67.08* | -- | -- | 2025 |
| Utah | $12.98* | -- | Required | 2026 |
| Wisconsin | $51.90 | -- | -- | 2025 |
Published Medicaid fee-for-service schedule amounts, not a coverage or eligibility guarantee. Managed-care plan rates can differ. Where no prior-authorization flag is shown, the state does not publish one. Rows marked * are representative published variants or methodology-derived rates. "--" in the prior-auth column means the state publishes no PA flag.
Related state-specific services codes
- C1716 - Brachytherapy source, non-stranded, gold-198, per source
- C1717 - Brachytherapy source, non-stranded, high dose rate iridium-192, per source
- C1719 - Brachytherapy source, non-stranded, non-high dose rate iridium-192, per source
- C2616 - Brachytherapy source, non-stranded, yttrium-90, per source
- C2634 - Brachytherapy source, non-stranded, high activity, iodine-125, greater than 1.01 mci (nist), per source
- C2635 - Brachytherapy source, non-stranded, high activity, palladium-103, greater than 2.2 mci (nist), per source
- C2636 - Brachytherapy linear source, non-stranded, palladium-103, per 1 mm
- C2638 - Brachytherapy source, stranded, iodine-125, per source
All 56 codes from Q5098 to Q5167 or every state-specific services code by number.
Frequently asked questions
How much does Medicaid pay for Q5145?
16 state Medicaid programs publish a fee-for-service rate for Q5145 (injection, adalimumab-afzb (abrilada), biosimilar, 1 mg), ranging from $12.98 in Utah to $128.07 in Arkansas. The full table on this page lists every publishing state's current rate.
Which state pays the most for Q5145?
Arkansas publishes the highest Medicaid rate for Q5145 at $128.07. Utah publishes the lowest at $12.98.
Does Q5145 require prior authorization under Medicaid?
3 of the 16 publishing states flag Q5145 as requiring prior authorization (always or conditionally) on their fee schedules. States without a flag publish no PA indicator for this code - that means "not published", not "no PA required".